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Abstract
Background. Elevated B-type natriuretic peptide (BNP) levels are predictive of cardiovascular events in patients on chronic maintenance haemodialysis, even in those without apparent cardiovascular disorders when they start dialysis. In the present study, we tested the hypothesis that left ventricular diastolic dysfunction increases BNP levels and can predict cardiovascular events in patients on chronic haemodialysis without apparent cardiac disease.
Methods. Patients on chronic maintenance haemodialysis in a stable condition and with normal systolic function were enrolled (n = 98). BNP concentrations were measured, and left ventricular diastolic function was assessed using echocardiography after the first dialysis session of the week. Then, they were followed up for 2 years with the end point being the incidence of cardiovascular events. Results. At baseline, left ventricular diastolic dysfunction was detected in 39 of 98 patients. After adjustment for known risk factors, multivariable regression analysis demonstrated that diastolic dysfunction was a significant predictor of increased BNP levels (P < 0.05). During the follow-up period, 17 patients experienced cardiovascular events. Kaplan-Meier analysis demonstrated that the incidence of cardiovascular events was higher in patients with (28.2%) than without (10.2%) left ventricular diastolic dysfunction (log-rank, P < 0.01). Univariate Cox proportional hazards regression analysis indicated that diastolic dysfunction and BNP were significant predictors of cardiovascular events (hazard ratio 3.63 and 4.87, respective
Introduction
The life expectancy of patients on chronic maintenance haemodialysis is lower than that of patients with similar demographics who are not on dialysis [1] . The increased mortality of patients on chronic haemodialysis is attributed mainly to cardiovascular disease, which is responsible for ∼50% of deaths in this patient group [2, 3] . Although the increased risk of cardiovascular disease in dialysis patients is most likely due to the severely compromised cardiovascular state at the time the patients commence haemodialysis, patients without any apparent cardiovascular disorder are also at an increased risk of future cardiovascular events. Thus, identifying dialysis patients with increased cardiovascular risk is of clinical importance and would enable preventative measures to be implemented.
In patients with cardiac disease, plasma B-type natriuretic peptide (BNP) levels increase in response to increases in left ventricular (LV) filling pressure or volume [4] [5] [6] [7] . Thus, circulating levels of BNP are used to evaluate the severity of the disease and to determine the prognosis for such patients [8] [9] [10] . Although BNP levels are higher in patients on chronic haemodialysis compared with those not on dialysis [11] [12] [13] [14] [15] , it has been shown that marked increases in BNP levels (>390 ng/L) in patients on chronic maintenance haemodialysis without any clinical signs of cardiovascular disease can be used to predict cardiovascular events [16] . However, in that report [16] , the mechanism underlying the marked increase in BNP levels in some asymptomatic haemodialysis patients was not clear. Indeed, in patients with elevated BNP levels, preserved LV systolic function was observed without any organic lesion. Conversely, the β-adrenergic receptor antagonist carvedilol reduces BNP levels in dialysis patients by improving LV diastolic function [17] . In line with this observation, BNP has been reported to be a reliable marker of LV diastolic [18] [19] [20] , as well as systolic [21, 22] , dysfunction.
Thus, in the present study, we tested the hypotheses that: (i) marked increases in BNP levels in some dialysis patients without cardiac disease are caused by impaired LV diastolic function; and (ii) LV diastolic dysfunction increases the risk of cardiovascular events in asymptomatic patients on chronic haemodialysis with preserved systolic function.
Materials and methods

Study design
The present study included a cross-sectional evaluation of the relationship between LV diastolic dysfunction and BNP levels, and a prospective observational end point study to assess the relationship between LV diastolic dysfunction and future cardiovascular events in patients on chronic haemodialysis with preserved LV systolic function. The study was performed in accordance with the principles of the Declaration of Helsinki, and the study protocol was approved by the Ethics Committee of Enshu Hospital. Written informed consent was obtained from all patients prior to the start of the study. Patients were followed up by investigators at Enshu Hospital.
Study subjects and procedures
From April to June 2005, 113 consecutive patients on chronic maintenance haemodialysis without apparent cardiovascular disease whose condition had been stable for at least the past 3 months were screened for their eligibility to enrol in the study. These patients had commenced haemodialysis between June 1992 and December 2004. Fourteen patients with LV systolic dysfunction were excluded from the study [LV fractional shortening (FS) 20.8 ± 2.7% (15.7-25.0%)]. Patients with normal LV systolic function (LV ejection fraction on echocardiography ≥50%) and a posthaemodialytic cardiothoracic ratio on chest X-ray <50% for men and <55% for women were enrolled in the study (n = 99; male/female = 60/39; mean age 65.4 ± 11.8 years; Figure 1) ; the plan was to follow up these patients over a period of 2 years. Patients were maintained on regular haemodialysis prescription, three times a week, for 4 h per session. All patients had distal arm arteriovenous fistulae and used high-flux polysulphone membranes, size-adjusted to be equal to each patient's body surface area (1.46 ± 0.39 m 2 ). The blood flow rate was 200 mL/min, with a dialysate flow rate of 500 mL/min. For all treatments, dialysate contained 140 mmol/L sodium, 2.0 mmol/L potassium, 3.0 mmol/L calcium, 1.0 mmol/L magnesium and 30.0 mmol/L bicarbonate. Blood was sampled for the measurement of BNP, and LV systolic and diastolic function was assessed by echocardiography after the first dialysis session of the week. Brachial blood pressure was measured after a 5-min rest in a supine position prior to the session of haemodialysis on the arm without arteriovenous fistulae using a semi-automated device (BP-103iII, Omron Colin, Tokyo, Japan). Three consecutive blood pressure measurements were taken, with 2 min between each measurement, and the mean of the second and third measurements was recorded as the blood pressure. The end point of the study was a composite of cardiovascular events, including: (i) sudden death; (ii) fatal and non-fatal myocardial infarction (detected by clinical symptoms, combined with Q-wave analysis, elevated ST segment, or both and elevated levels of cardiac enzymes); (iii) unstable angina pectoris requiring hospitalization; (iv) congestive heart failure requiring hospitalization [New York Heart Association (NYHA) class III or IV; the diagnosis was based on Framingham criteria [23] ]; (v) severe arrhythmia (ventricular tachycardia and ventricular fibrillation); and (vi) fatal or non-fatal stroke. The exclusion criteria for the present study included: a history of cardiovascular disease including myocardial infarction, angina pectoris, stroke or cardiac revascularization; severe valvular heart disease; congestive heart failure; severe arrhythmia; atrial fibrillation; peripheral artery disease; and pulmonary, hepatic, active inflammatory and malignant diseases.
The difference between the pre-dialysis weight and the weight at the end of the previous dialysis session divided by the number of the interdialytic days was considered to be interdialytic weight gain. The average of interdialytic weight gain during 14 days (7 days before and 7 days after the baseline examination of echocardiography) was calculated and used for analysis. The percentage relationship between the average interdialytic weight gain and the patient's dry weight was also obtained.
Measurement of plasma BNP concentrations
To measure BNP, 3-mL blood was transferred to plastic tubes containing 4.5 mg 2Na-EDTA. Plasma samples were prepared within 30 min by pre-cooled centrifuge, frozen immediately and stored at −70°C until analysis. The BNP concentration was determined using a commercially available chemiluminescence enzyme immunoassay (MI02 Shionogi BNP kit; Shionogi, Osaka, Japan). The intra-and interassay coefficients of variation of the BNP assay were 4.0% and 4.7%, respectively. The lower limit of detection of the assay was 2.0 ng/L BNP. [24] . The LV ejection fraction (LVEF) and FS were calculated from M-mode images using the formula of Teicholz et al. [25] . LV mass was calculated using the method described by Devereux and Reichek [26] . LV systolic function was considered to be normal when LVEF was ≥50%, and abnormal LV wall motion was not observed. Transmitral pulsed Doppler velocity recordings from three consecutive cardiac cycles were used to derive measurements for early diastole (E) and atrial (A) filling velocities, deceleration time (DT; the interval from the peak of the E-wave to the Fig. 1 . Flow of patients on chronic maintenance haemodialysis through the study. The exclusion criteria were ischaemic heart disease, severe valvular heart disease, congestive heart failure, severe arrhythmia, atrial fibrillation, and pulmonary, hepatic, active inflammatory and malignant diseases. Data show the number of patients in each group, with percentages given in parentheses. P-values were assessed by Yates' corrected chi-square test. Hypertension was defined as systolic blood pressure ≥140 mmHg, diastolic blood pressure ≥90 mmHg or the use of antihypertensive medications. Diabetes mellitus was defined as fasting plasma glucose ≥126 mg/dL or the use of antidiabetic medications, and hyperlipidaemia was defined as total cholesterol >220 mg/dL, triglyceride >150 mg/dL or the use of antihyperlipidaemic medications. decline of velocity to baseline), and isovolumetric relaxation time (IVRT). LV diastolic dysfunction was divided into three categories: impaired relaxation, pseudonormal and restrictive-like filling patterns. Impaired relaxation was defined as an E/A ratio <1 or DT >240 ms in patients <55 years of age and an E/A ratio <0.8 and DT >240 ms in patients ≥55 years of age. For all patients, regardless of age, pseudonormal was defined as an E/A ratio of 1-1.5 and DT >240 ms, whereas restrictive-like filling patterns were defined as DT <160 ms with one of the following: LAD >5 cm, E/A >1.5 or IVRT <70 ms [18] . All findings were interpreted by experienced cardiologists, who were blinded to the clinical information and laboratory data.
Statistical analysis
Differences between two means of normal distribution were compared by unpaired Student's t-test. Because the distribution for BNP, parathyroid hormone and C-reactive protein concentrations, and the duration of haemodialysis and observation period were skewed to the right, median values were computed, and data are expressed as the median ± median absolute deviation. The significance of differences between median values was assessed by the Mann-Whitney U-test. Yates' corrected chi-square test was used to compare categorical data. The relationship between BNP levels and variables, including LV diastolic dysfunction obtained at baseline, was examined using multivariable regression analysis. To evaluate the effect of LV diastolic dysfunction, cumulative event-free curves were determined by the Kaplan-Meier method, and differences between patients with and without LV diastolic dysfunction were analysed using the log-rank test. Univariate Cox proportional hazards regression analysis was used to calculate hazard ratios and 95% confidence intervals (CIs) of cardiovascular events for baseline characteristics. In all cases, P < 0.05 was considered significant. All analyses were performed using SPSS software, version 11 (SPSS Inc., Chicago, IL, USA). Based on previous data, the assumed rate of composite cardiovascular events in patients on chronic maintenance haemodialysis who were in a stable condition was 15-20 per 100 patient-years [16, 27] . The present study was designed to investigate whether LV diastolic dysfunction would increase the risk of cardiovascular events based on the assumption that the event-free survival rate was 0.6 and 0.9 in patients with and without diastolic dysfunction, respectively. To achieve a power of 80% with a twosided test of significance at an α level of 0.05, 37 patients were required per arm of the study. With the added expectation of subjects withdrawing from the study, we planned to recruit 40 subjects for each group. The number of patients enrolled in the study with LV diastolic dysfunction was less than the number of patients without diastolic dysfunction because we enrolled patients without LV systolic dysfunction consecutively until the number of patients in both groups was above 40. Because one of the patients with LV diastolic dysfunction withdrew consent to participate in the study, data for 98 patients were available for final analysis. Figure 1 , echocardiography demonstrated that 40 of 99 patients (39 of 98 patients after excluding one patient who withdrew the consent) with normal LV * P < 0.05 for patients with and without diastolic dysfunction (Yates' corrected chi-square test). Fig. 2 . Kaplan-Meier analysis of the cumulative cardiovascular eventfree rate in patients on chronic haemodialysis (*P = 0.0072). systolic function had LV diastolic dysfunction (impaired relaxation = 32; pseudonormal = 4; restrictive-like filling = 3). There were no significant differences in baseline characteristics (Table 1) , medication, and risk factors (Table 2) between patients with and without LV diastolic dysfunction, except for BNP levels. BNP levels were higher in patients with LV diastolic dysfunction (249 ± 154, 395 ± 48 and 803 ± 142 ng/L for those with impaired relaxation, pseudonormal and restrictive-like filling patters, respectively) than in patients without LV diastolic dysfunction (Table 1) . Kt/V was not correlated with BNP levels at baseline (r = 0.01, P = 0.91). Echocardiography indicated that DT, LVDd, LVDs, LVPWT and LV mass index (LVMI) were greater in patients with than in those without LV diastolic dysfunction (Table 3) . Multivariable regression analysis demonstrated that gender, LAD, interdialytic weight gain and diastolic dysfunction were significant predictors of BNP levels in dialysis patients after adjusting for age, BMI, hypertension, diabetes mellitus, hyperlipidaemia, haemoglobin, albumin, parathyroid hormone, C-reactive protein and LVMI (Table 4) .
Results
As shown in
Seventeen patients experienced cardiovascular events during the follow-up period. The incidence of composite cardiovascular events was 18% less in patients without diastolic dysfunction compared with those with diastolic dysfunction (Table 5) . Kaplan-Meier analysis indicated that the incidence of cardiovascular events was significantly higher in patients with than in those without LV diastolic dysfunction (log-rank P = 0.0072; Figure 2 ). Univariate Cox proportional hazards regression analysis was also performed to investigate possible relationships between characteristics at baseline and cardiovascular events (Table 6 ). In this analysis, age, BNP and diastolic dysfunction were found to be significant predictors of primary outcome.
Discussion
The present study has demonstrated that both LV diastolic dysfunction and BNP are predictors of future cardiac events in patients on chronic maintenance haemodialysis, and increased levels of BNP are closely associated with impaired LV diastolic function.
Although BNP levels are generally higher in patients on chronic haemodialysis compared with patients with normal kidney function [11] [12] [13] [14] [15] , a marked increase in BNP levels (>390 ng/L) indicates an increased risk of cardiovascular events or mortality in dialysis patients, even in the absence of clinical signs of cardiovascular disease [16] . However, the mechanisms underlying the increases in BNP levels in some dialysis patients with apparently normal cardiac function remain unknown. The results of the present study suggest that impaired LV relaxation underlies the increase in BNP levels in this population of patients. Because BNP is secreted in response to an increase in LV filling pressure [4] [5] [6] [7] , LV diastolic dysfunction in some patients may stimulate the secretion of BNP. Indeed, circulating levels of BNP are elevated in proportion with the degree of LV diastolic dysfunction in patients with preserved LV systolic function [18] [19] [20] .
In the present study, patients with diastolic dysfunction had a greater LVMI in addition to increased levels of BNP, which is compatible with previous reports that increased concentrations of BNP are associated with LV hypertrophy [28, 29] , one of the most important risk factors for cardiovascular events. However, in the present study, there was no independent correlation between BNP levels and LVMI. This may have been due to the relatively narrow range of LVMI obtained for the patients in the present series who were in a stable condition and who apparently did not have any cardiac disease. Alternatively, it may be that there are different mechanisms responsible for LV hypertrophy and diastolic dysfunction, and that diastolic dysfunction has a greater impact on BNP levels than LV hypertrophy.
The findings of the present cross-sectional analysis, together with previous findings that BNP is a significant predictor of cardiovascular events in patients on chronic haemodialysis, raise the question as to whether diastolic dysfunction itself can predict cardiovascular events. During the median 17-month follow-up period, 17.3% of patients experienced cardiovascular events, confirming that dialysis patients have a high risk of cardiovascular events even though they have no signs of cardiac disease. The incidence of cardiovascular events was lower in patients without LV diastolic dysfunction; furthermore, KaplanMeier analysis indicated that there was a higher cumulative incidence rate of cardiovascular events in patients with LV diastolic dysfunction compared with patients without any diastolic dysfunction. These results clearly show that LV diastolic dysfunction at baseline is an important determinant of the future incidence of cardiovascular events in patients on chronic haemodialysis. Moreover, univariate Cox proportional hazards regression analysis indicated that LV diastolic dysfunction and BNP were predictors of cardiovascular events in our patient population. These results strongly support our hypothesis that increased BNP levels in some dialysis patients without cardiac disease can be attributed to impaired LV diastolic function and that LV diastolic dysfunction increases the risk of cardiovascular events in haemodialysis patients with preserved systolic function. This, in turn, supports the concept that effective treatment of LV diastolic dysfunction, if possible, may improve the prognosis for such patients [17] . Although LAD was independently related with BNP levels in crosssectional analysis at baseline, the index was not a predictor of cardiovascular events. The present result seems to be incompatible with previous reports that LA volume was a predictor of cardiovascular events in patients on haemodialysis [30, 31] . However, LAD is inferior to LA volume as a predictor of cardiovascular events [30, 31] , which might be the reason for the discrepancy. The degree of interdialytic fluid retention is also potentially important. Recent study demonstrated that greater interdialytic weight gain is associated with poor cardiovascular survival [32] . However, in the present study, interdialytic weight gain was not a significant predictor of cardiovascular events. The apparent discrepancy between the previous and the present studies may be attributable to the difference in patient characteristics. In the present study, patients under a stable condition with normal cardiothoracic ratio on chest X-ray were enrolled, and thus, most of our patients showed mild interdialytic weight gain. This may be the reason why this index was not predictive of cardiovascular events in our study.
The lower incidence of heart failure in the patient subgroup without LV diastolic dysfunction in the present study is as expected because LV diastolic dysfunction is a common cause of heart failure [33] . However, in the present study, the incidence of each component of the primary outcome (i.e. sudden death, unstable angina and ischaemic stroke) tended to be lower in patients without than in those with LV diastolic dysfunction. Although the reason why diastolic dysfunction or elevated BNP predicts these cardiovascular events is not clear, several mechanisms are speculated. An elevation of BNP levels is closely associated with myocardial ischaemia [34] . Myocardial ischaemia can be a trigger of ventricular arrhythmia and generally reflects systemic progression of atherosclerosis that may underlie the pathophysiological changes related to stroke. Indeed, elevated BNP is associated with the risk of stroke [35, 36] . Alternatively, increased left ventricular end-diastolic pressure that accompanies diastolic dysfunction may have caused complex arrhythmia.
Interpretation of the present data is limited due to the following conditions. First, the number of patients included in the present study was small, and the follow-up period was relatively short. Further studies with a larger number of patients and conducted over a longer period are necessary to clarify the role of LV diastolic dysfunction and BNP levels in increased cardiovascular risk for dialysis patients with preserved LV systolic function. Second, echocardiographic parameters should be interpreted with caution because LV dimensions change significantly over the course of a haemodialysis session [37] . Third, LV mass and function (systolic and diastolic function, and focal wall motion) would have been better assessed using recently developed modalities or techniques such as magnetic resonance imaging, two-dimensional speckle tracking and tissue Doppler imaging on echocardiography [38] [39] [40] . There may be a risk of overestimating LV mass with echocardiography and of missing abnormal LV wall motion without using two-dimensional speckle-tracing method. Fourth, cardiac function and BNP concentrations may be affected by the flow status through arteriovenous fistulae [41] , and BNP levels may be affected by residual renal function which was not measured in the present study, clearance of the peptide by dialysis [42] , and chronic volume overload status [43] . Fifth, circulating BNP levels are reduced after a dialysis session [42, 44] , possibly due to the clearance and reduced production of the peptide. Thus, the timing of BNP sampling may affect the results. Finally, we defined dry weight on the basis of clinical findings without an estimation of extracellular volume using bio-impedance analysis. This might result in fluid overload in dialysis patients. These points should be noted when interpreting the present data. Interventional studies aiming at correcting the chronic fluid overload of these patients should be undertaken in order to decrease BNP levels and perhaps improve the diastolic dysfunction.
In conclusion, elevated BNP levels, which are predictive of cardiovascular events in patients on chronic maintenance haemodialysis without cardiac disease, are closely associated with impaired LV diastolic function. LV diastolic dysfunction as well as elevated BNP is a predictor of future cardiac events in such patients.
